• Patient Stories
  • Understanding MPNs
    • Understanding MPNS
    • What Is Polycythemia Vera?
    • What Is Essential Thrombocythemia?
    • What Is Primary Myelofibrosis?
  • Resources
    • Empowered Patients
    • Dictionary
    • Resources
  • Partners
    • Industry Partners
    • International MPN Organizations
    • Partners
  • News Feed
  • Contact
  • MPN Search

PV Reporter

MPN Information and Research Hub

  • About
    • About Us
    • MPN Cancer Connection
    • Contact Us
  • MPN Specialists
  • Blog
  • Media
    • Podcast
      • 01: Polycythemia Vera Diagnosis, PV Reporter, Day 1, Doomsday or Living with a Plan
      • 02: MPN Chronicles – Interview with Dr. Pemmaraju
      • 03: Learn Benefits of Becoming your own MPN Advocate
      • 04: First Hematologist appointment for PV patient
      • 05: Tips to Living Well with an MPN
      • 06: My Plan to beat Coronavirus Blues
    • Videos
    • Dr. Interviews
      • Dr. Jean Jacques Kiladjian ASH 2018 RuxoPeg Phase 1/2 Trial of the Combo of Ruxolitinib and Pegasys in Myelofibrosis Patients
      • Dr. Michael Grunwald ASH 2018 Risk Assessment and Treatment Myelofibrosis Patients at Community Oncology Practices in the U.S.
      • Dr. J.J. Kiladjian ASH 2018 Headline Research Studies
      • ASH 2017 Interview with Dr. Michael Grunwald
        • ASH 2017 Interview with Dr. Raajit Rampal, part 1
        • ASH 2017 with Dr. Raajit Rampal, part 2
        • ASH 2017 Interview with Dr. Jean Jacques Kiladjian, part 1
        • ASH 2017 Interview with Dr. Jean Jacques Kiladjian, part 2
      • ASH 2016 Interviews
        • ASH 2016 Interview with Dr Kiladjian
        • ASH 2016 Interview with Dr Rampal
      • ASH 2015 Interviews
        • ASH 2015 Interview with Dr John Mascarenhas
        • ASH 2015 Interview with Dr Angela Fleischman
      • ASH 2014 Interviews
        • ASH 2014 Interview with Dr Heinz Gisslinger
        • ASH 2014 interview with Dr Richard Stone
  • Treatment
    • How I Treat MPN’s
    • Jakafi
    • INREBIC
    • Interferon treatment for MPNs
  • Support Group

Clinical Trial Finder

Search Results

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Study Purpose

This study is an open label, phase IIa trial in subjects with Myelofibrosis

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

Participants must satisfy all of the following criteria at the Screening visit: 1. Adult male or female participants ≥ 18 years of age at enrolment: 1. Female participants may be of non-childbearing potential defined as permanently sterile or postmenopausal, or female participants considered to be of childbearing potential who agree to use highly effective birth control methods until 90 days after the follow-up visit. Female participants should refrain from ova donation from the date of Enrolment (Day -1) until 90 days after the follow-up visit. 2. Male participants will agree to use contraception throughout the study and until 90-days after the Follow-up visit. Male participants must agree to refrain from sperm donation from the date of Enrolment (Day -1) until 90 days after the follow-up visit. 2. Diagnosis of PMF or SMF with intermediate -2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS)-plus or if with low risk disease then with symptomatic splenomegaly as defined by sonographic assessment as spleen length of >12 cm or by physical examination as ≥ 5 cm below left costal margin. 3. Participants who are not currently taking a Janus kinase (JAK) inhibitor (e.g. ruxolitinib or fedratinib) and are therefore refractory, intolerant or ineligible for a JAK inhibitor according to appropriate guidelines (including local guidelines). 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 5. Required baseline laboratory status: 1. Absolute platelet count (APC) ≥ 50 x 109/L. 2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1500/mm3) 3. Serum direct bilirubin ≤ 2.0 x ULN (upper limit of normal) 4. AST (SGOT) or ALT (SGPT) [if both measured, then this applies to both measurements] ≤ 2.5 x ULN, except for participants with MF involvement of the liver who must have levels ≤ 5 x ULN. 5. Estimated Glomerular Filtration Rate (eGFR) or creatinine clearance (CrCl) (CrCl calculated by the Cockroft and Gault method) ≥ 30 ml/min/1.73 m2. 6. Peripheral blood blasts <10% 6. Treatment-related toxicities from prior therapies must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1. 7. Participants must have a documented history of transfusion records (if there have been any such transfusions) in the preceding 12 weeks to Day 1.

Exclusion Criteria:

1. Current treatment with a JAK inhibitor (e.g. ruxolitinib or fedratinib) or a history of treatment with a JAK inhibitor within two weeks of enrolment. 2. Positive hepatitis panel and/or positive HIV test. 3. Any concurrent severe and/or uncontrolled medical conditions that could increase the participant's risk for toxicity while in the study or that could confound discrimination between disease- and study treatment-related toxicities. Any planned major surgery during the study period. 4. Impaired cardiac function or clinically significant cardiac diseases, including any of the following: 1. History or presence of ventricular tachyarrhythmia. 2. Presence of unstable atrial fibrillation (ventricular response > 100 bpm); Participants with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria. 3. Clinically significant resting bradycardia (< 50 bpm) and use of a cardiac pacemaker or implantable cardioverter defibrillator. 4. Angina pectoris or acute myocardial infarction ≤ 90 days prior to starting study drug. 5. Other clinically significant heart disease (e.g., symptomatic congestive heart failure; uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen). 5. Participants who are currently receiving chronic (> 14 days) treatment with corticosteroids at a dose > 10 mg of prednisone (or its glucocorticoid equivalent) per day, or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug. 6. Participants with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GB2064 as per physician's opinion. 7. Participants who received radiotherapy within the last month prior to screening procedures, or patients who received splenectomy in the previous three months or are scheduled for the procedure in the next three months. 8. Participants who had a history of malignancy in the past 3 years, except for treated early stage squamous, basal cell carcinoma or treated, localised prostate cancer. 9. Presence of clinically meaningful active bacterial, fungal, parasitic or viral infection which requires therapy. 10. Previous history of Progressive Multifocal Leuko-encephalopathy (PML). 11. Pregnant or breast feeding (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive β- HCG laboratory test. 12. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 90 days after study treatment. Highly effective contraception methods must be used. 13. Sexually active males must use a condom during intercourse while taking the drug and for 90 days after stopping study drug and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. 14. Hypersensitivity to GB2064 and/or its excipients. 15. Participants unable or unwilling to comply with protocol requirements. 16. Participants related to PI/site staff. 17. Participants who have had a hematopoietic stem cell transplantation. 18. Participants who are eligible, have a donor and are willing to undergo a hematopoietic stem cell transplantation.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04679870
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Galecto Biotech AB
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Srdan Verstovsek, MD, PhD
Principal Investigator Affiliation The University of Texas MD Anderson Cancer Center, Houston, TX
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry, Other
Overall Status Recruiting
Countries Australia, Germany, Italy, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Myelofibrosis
Additional Details

This study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GB2064 a LOXL-2 inhibitor over 9 months. Subjects will receive doses of GB2064, given twice per day to participants with primary or secondary Myelofibrosis

Arms & Interventions

Arms

Experimental: GB2064

GB2064 will be administered orally as 4 x 250 mg tablets twice a day.

Interventions

Drug: - GB2064

GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

MD Andersson Cancer Hospital, Houston, Texas

Status

Recruiting

Address

MD Andersson Cancer Hospital

Houston, Texas, 77030

Site Contact

Srdan Verstovsek, MD

Clinicaltrials@galecto.com

+4570705210

International Sites

Woden Dermatology, Canberra, Australia

Status

Recruiting

Address

Woden Dermatology

Canberra, , 2605

Site Contact

Dipti Talaulikar, MD

Clinicaltrials@galecto.com

+4570705210

Heinrich-Heine-University Dusseldorf, Düsseldorf, Germany

Status

Recruiting

Address

Heinrich-Heine-University Dusseldorf

Düsseldorf, , 40225

Site Contact

Norbert Gattermann, MD

Clinicaltrials@galecto.com

+4570705210

Universitätsklinikum Heidelberg, Heidelberg, Germany

Status

Recruiting

Address

Universitätsklinikum Heidelberg

Heidelberg, , 69120

Site Contact

Richard Schlenk, MD

Clinicaltrials@galecto.com

+4570705210

Universität Leipzig, Leipzig, Germany

Status

Recruiting

Address

Universität Leipzig

Leipzig, , 04103

Site Contact

Georg-Nikolaus Franke, MD

Clinicaltrials@galecto.com

+4570705210

München, Germany

Status

Withdrawn

Address

Praxis für Haemathologie and Onkologie am Isartor

München, , 80331

Site Contact

Clinicaltrials@galecto.com

+4570705210

München, Germany

Status

Recruiting

Address

Klinikum rechts der Isar der Technischen Universitaet Munchen

München, , 81675

Site Contact

Peter Herhaus, MD

Clinicaltrials@galecto.com

+4570705210

Bologna, Italy

Status

Recruiting

Address

University of Bologna Sant Orsola Malpighi

Bologna, , 40138

Site Contact

Francesca Palandri, MD

Clinicaltrials@galecto.com

+4570705210

Firenze, Italy

Status

Recruiting

Address

Azienda Ospedaliero-Universitaria Careggi

Firenze, , 50134

Site Contact

Francesco Mannelli, MD

Clinicaltrials@galecto.com

+4570705210

Milano, Italy

Status

Recruiting

Address

ASST Grande Ospedale Metropolitano Niguarda

Milano, , 20162

Site Contact

Marianna Caramella, MD

Clinicaltrials@galecto.com

+4570705210

Orbassano, Italy

Status

Recruiting

Address

Azienda Ospedaliero-Universitaria San Luigi Gonzaga di Orbassano

Orbassano, , 10043

Site Contact

Daniela Cilloni, MD

Clinicaltrials@galecto.com

+4570705210

Varese, Italy

Status

Recruiting

Address

Azienda Socio-Sanitaria Territoriale dei Sette Laghi

Varese, , 21100

Site Contact

Francesco Passamonti, MD

Clinicaltrials@galecto.com

+4570705210

Powered By
The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

RSS MPN News

  • Contemporary Approach CALR Positive MPNs
  • 9 Tips to Reduce MPN Fatigue
  • Common Clinical Trial Acronyms and Abbreviations
  • Understanding the Phases of Clinical Trials
  • 4th Angel providing one-on-one support services for MPN Patients

MPN 2019 guidelines

MPN 2019 Guidelines, PV Reporter

Click on the image above for the New MPN Patient Guidelines! Very detailed, provided by NCCN.

Medical Dislaimer

Sign up for Our Newsletter!

Copyright · PV Reporter © 2021 · Site Design by David Wallace
error: